Repurposing base editors for targeted knock-in and simultaneous multiplex knockouts to generate allo-CAR T cells with minimal translocations.
Compared with multiplex Cas9 editing, BEKI markedly reduced chromosomal translocations while preserving cell viability, and provides a streamlined and scalable strategy for multiplex CAR T-cell engineering with improved genomic stability, advancing safer next-generation cell therapies for cancer and autoimmune diseases.